Fig. 1 · Structure

Documents & Downloads

Germacrone

Cat. No. A14488 CAS 6902-91-6
Germacrone is an antiviral isolate of Geranium macrorrhizum.

In Stock

Publications for Germacrone

1 publication citing this product

  1. Liujie Zheng, .et al. , The FASEB Journal, 2026, 40(4): e71580 PMID: 41677398

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In human RPTEC/TERT1 renal tubular cells, germacrone pretreatment and cotreatment reduced intracellular platinum accumulation during cisplatin exposure. This supports an uptake-related component of its reported renal-cell protection; it does not establish exclusive transporter dependence. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Germacrone Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Germacrone from 3 published references. In vitro models include human RPTEC/TERT1 renal proximal tubular cells; human PC-3 and 22RV1 prostate cancer cell lines.

Germacrone In Vitro Studies

Germacrone at 50–100 µM attenuated cisplatin-associated loss of viability in RPTEC/TERT1 cells after 1 h pretreatment followed by 48 h cotreatment with 50 µM cisplatin. Apoptosis measurements supported protection in this renal-cell model. [1]

In PC-3 and 22RV1 prostate cancer cells, the reported 48 h MTT IC50 values were 259 and 396.9 µM, respectively. Germacrone also increased apoptosis. Adding 50 µM chloroquine during the final 6 h of a 48 h exposure to 240 µM germacrone further reduced viability and increased apoptosis; chloroquine alone also affected these endpoints. [2]

Germacrone attenuates cisplatin cytotoxicity in renal tubular cells

Cell-based study · Human RPTEC/TERT1 renal proximal tubular cells [1]

Germacrone pretreatment and cotreatment attenuated the cisplatin-associated loss of MTT viability. Annexin V/PI and Bcl-2 measurements supported reduced apoptosis. Vehicle, cisplatin-alone and germacrone-alone groups were included. This is cell-based protection against a defined chemical insult.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cisplatin-associated loss of renal-cell viabilityQualitative comparison Attenuated by 50 and 100 µM germacrone[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 and 100 µM germacrone; 50 µM cisplatin
Exposure duration
1 h germacrone pretreatment for combination groups, followed by 48 h cisplatin plus germacrone
Method
Cell treatment; MTT, Annexin V-FITC/PI flow cytometry and Bcl-2 immunoblotting
Vehicle
Vehicle-treated control reported; vehicle composition not specified
Co-treatment
Cisplatin cotreatment; protection is not a germacrone-alone anticancer endpoint.
Reported limits
Germacrone purity and treatment vehicle composition are not specified. Figure 1B/C do not separately label the germacrone concentration; no concentration-specific apoptosis magnitude is assigned.
Methods and source locations

Compound reported in the paper: Germacrone; Compound label in the paper: germacrone

Evidence applies to the reported germacrone material and experimental model; no current Adooq lot equivalence or human efficacy is established.

Figure 1A–C and caption; Results: Effect of Germacrone on Cisplatin-Induced Cell Death; Methods: Chemicals, Cell Viability Assay, Cell Apoptosis, Western Blot Analysis

Cisplatin-associated loss of renal-cell viability: MTT; three independent experiments, mean ± S.D. — Figure 1A and caption; first Results subsection

Germacrone reduces intracellular platinum accumulation

Cell-based study · Human RPTEC/TERT1 renal proximal tubular cells [1]

Cells exposed to cisplatin plus germacrone accumulated less platinum than cells exposed to cisplatin alone. The OCT inhibitor tetrapentylammonium (TPeA) served as a mechanistic comparator. This supports an uptake-related component of protection, without establishing a human OCT2 binding constant or transporter exclusivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intracellular platinum relative to cisplatin aloneQualitative comparison Lower with germacrone cotreatment[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 µM germacrone plus 100 µM cisplatin; comparator 1 mM TPeA plus 100 µM cisplatin
Exposure duration
1 h germacrone or TPeA pretreatment, followed by 4 h cisplatin cotreatment
Method
Cellular platinum determination by flame furnace atomic absorption spectrophotometry
Vehicle
Cisplatin-alone comparator; treatment vehicle composition not specified
Co-treatment
Cisplatin; separate TPeA comparator
Reported limits
No exact percentage reduction is extracted from the plot. The separate OCT uptake assay has unresolved 1-versus-5-min reporting and its potency is withheld.
Methods and source locations

Compound reported in the paper: Germacrone; Compound label in the paper: germacrone

Evidence applies to the reported germacrone material and experimental model; no current Adooq lot equivalence or human efficacy is established.

Figure 2A and caption; Results: Effect of Germacrone on Cellular Accumulation of Cisplatin; Methods: Intracellular Accumulation of Platinum

Intracellular platinum relative to cisplatin alone: Atomic absorption spectrophotometry; three independent experiments; no numerical magnitude or p-value assigned to the Figure 2A comparison — Figure 2A; Results: Effect of Germacrone on Cellular Accumulation of Cisplatin

Germacrone lowers prostate cancer-cell viability

Cell-based study · Human PC-3 and 22RV1 prostate cancer cell lines [2]

After 48 h, germacrone decreased MTT viability with reported IC50 values of 259 µM in PC-3 and 396.9 µM in 22RV1. Annexin V/PI analysis at 240 µM also showed increased apoptosis. These are in vitro assay endpoints.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PC-3 MTT viability after 48 hIC50 259 µM[2]
22RV1 MTT viability after 48 hIC50 396.9 µM[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 30, 60, 120, 240 and 480 µM for MTT; 240 µM for the apoptosis comparison
Exposure duration
48 h
Method
MTT viability and Annexin V/PI flow cytometry
Vehicle
Untreated/0 µM control; treatment solvent not specified
Co-treatment
None in the adopted monotherapy comparison
Reported limits
Replicate n and treatment vehicle are not specified in the read methods/captions. No uncertainty interval is reported for the IC50 values.
Methods and source locations

Compound reported in the paper: Germacrone; Compound label in the paper: germacrone

Evidence applies to the reported germacrone material and experimental model; no current Adooq lot equivalence or human efficacy is established.

Figure 2 and caption; Figure 3 monotherapy/control panels; Results: Germacrone Decreased the Viability and Induced the Apoptosis; Methods: MTT Assay and Detection of Apoptosis

PC-3 MTT viability after 48 h: MTT, 48 h; value stated in Results, not inferred from curve — Results: Germacrone Decreased the Viability and Induced the Apoptosis; Figure 2

22RV1 MTT viability after 48 h: MTT, 48 h; value stated in Results, not inferred from curve — Results: Germacrone Decreased the Viability and Induced the Apoptosis; Figure 2

Chloroquine enhances germacrone-associated cell death

Cell-based study · Human PC-3 and 22RV1 prostate cancer cells; control, germacrone, chloroquine and combination groups [2]

Adding chloroquine during the final 6 h of germacrone exposure further lowered MTT viability and increased Annexin V/PI apoptosis compared with germacrone alone. Chloroquine alone also affected these endpoints. The interaction is compatible with the paper’s protective-autophagy interpretation, but pharmacological cotreatment does not establish a specific autophagy-dependent mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Viability and apoptosis with germacrone plus CQ versus germacrone aloneQualitative comparison Lower MTT viability and greater Annexin V/PI apoptosis with cotreatment[2]

Literature-Reported Treatment Conditions

Treatment concentration
240 µM germacrone; 50 µM chloroquine (CQ)
Exposure duration
48 h germacrone exposure; CQ added for the final 6 h
Method
MTT viability and Annexin V/PI flow cytometry
Vehicle
Untreated control; solvent composition not specified
Co-treatment
Chloroquine; all four single/combination/control conditions shown
Reported limits
Replicate n and treatment vehicle not specified. Exact numerical apoptosis values are not adopted; representative scatter and group summary bars are not interchangeable.
Methods and source locations

Compound reported in the paper: Germacrone; Compound label in the paper: germacrone

Evidence applies to the reported germacrone material and experimental model; no current Adooq lot equivalence or human efficacy is established.

Figures 3 and 7 with captions; Results: Inhibiting Autophagy Promoted Germacrone-Induced Apoptosis; Methods: Detection of Apoptosis, Western Blotting, Statistical Analysis

Viability and apoptosis with germacrone plus CQ versus germacrone alone: Four-condition comparison; means ± SD per general statistical methods — Figures 3 and 7; Results: Inhibiting Autophagy Promoted Germacrone-Induced Apoptosis

Germacrone In Vivo Studies

In a 786-O renal-cancer xenograft mouse model, daily intraperitoneal germacrone at 60 or 90 mg/kg for 24 days delayed tumor growth. Terminal tumor weights were reported as 67.6% and 48.8% of vehicle control, respectively. Body weight and the measured liver/kidney serum markers showed no significant differences from control within this experiment. [3]

Germacrone suppresses renal-cancer xenograft growth

Animal study · Male BALB/c nude mice bearing subcutaneous human 786-O renal-cell carcinoma xenografts; n=5/group, randomized to four groups [3]

Daily intraperitoneal germacrone delayed tumor growth. Tumor weights were reported as 67.6% and 48.8% of control at 60 and 90 mg/kg/day. Body weight and serum AST, ALT, BUN and creatinine did not differ significantly between germacrone and control groups in this experiment. These limited observations do not establish general safety.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Terminal xenograft tumor weight relative to controlPercent of control 60 mg/kg/day: 67.6%; 90 mg/kg/day: 48.8%[3]
Body weight and serum AST, ALT, BUN, creatinineQualitative comparison No significant difference from vehicle control in the reported experiment[3]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Daily
Treatment course
24 days; treatment began 8 days after tumor inoculation; harvest on day 32
Vehicle
Control injection: 100 µL PEG400/DMSO/sterile deionized water, 1:1:3; germacrone injectate composition not separately specified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Germacrone 60 mg/kg/dayVehicle-injected tumor-bearing control; separate positive comparator received sunitinib 40 mg/kg/day by oral gavageTumor weight reported as 67.6% of control; tumor growth delayed[3]
Germacrone 90 mg/kg/dayVehicle-injected tumor-bearing control; separate positive comparator received sunitinib 40 mg/kg/day by oral gavageTumor weight reported as 48.8% of control; tumor growth delayed[3]
Germacrone 60 mg/kg/day
Model: Male BALB/c nude mice, 4 weeks old; subcutaneous 786-O xenografts; n=5/group
Reported limits: No pharmacokinetic exposure measurements; cannot infer human dose or long-term safety.
Germacrone 90 mg/kg/day
Model: Male BALB/c nude mice, 4 weeks old; subcutaneous 786-O xenografts; n=5/group
Reported limits: No pharmacokinetic exposure measurements; cannot infer human dose or long-term safety.
Methods and source locations

Compound reported in the paper: Germacrone; Compound label in the paper: germacrone

Evidence applies to the reported germacrone material and experimental model; no current Adooq lot equivalence or human efficacy is established.

Methods: Cell cultures, In vivo tumorigenicity assay, Hepatic and renal function analysis, histology, Statistical analysis; Figure 4 and caption; xenograft Results

Terminal xenograft tumor weight relative to control: Tumor weight at day 32; n=5/group; Figure 4 error bars mean ± SEM — Results: Germacrone repressed RCC xenograft tumor growth in vivo; Figure 4E

Body weight and serum AST, ALT, BUN, creatinine: Serial body weight and terminal serum biochemical assays; not a comprehensive toxicity assessment — Figure 4D,F and caption; xenograft Results; Methods: Hepatic and renal function analysis

Germacrone 60 mg/kg/day · Methods: In vivo tumorigenicity assay; Results: Germacrone repressed RCC xenograft tumor growth in vivo; Figure 4A–F

Germacrone 90 mg/kg/day · Methods: In vivo tumorigenicity assay; Results: Germacrone repressed RCC xenograft tumor growth in vivo; Figure 4A–F

Specifications

Manufacturer Adooq Bioscience
CAS Number 6902-91-6
Formula C15H22O
Molecular Weight 218.33
SMILES
CC1=CCC(=C(C)C)C(=O)CC(=CCC1)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 41 mg/mL (187.78 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Germacrone Research References

  1. [1] Sirima Soodvilai, Paranee Meetam, Lawan Siangjong, et al. Germacrone Reduces Cisplatin-Induced Toxicity of Renal Proximal Tubular Cells via Inhibition of Organic Cation Transporter Biological & pharmaceutical bulletin (2020). PMID: 33132314 DOI: 10.1248/bpb.b20-00392 Source material
  2. [2] Ziqiang Yu, Jiuping Xu, Mingfeng Shao, et al. Germacrone Induces Apoptosis as Well as Protective Autophagy in Human Prostate Cancer Cells Cancer management and research (2020). PMID: 32547235 DOI: 10.2147/cmar.s250522 Source material
  3. [3] Binqi Wang, Ruikai Zhang, Mengting Wu, et al. Germacrone suppresses renal cancer growth by regulating c-Fos-mediated lipid metabolism Lipids in health and disease (2026). PMID: 41832498 DOI: 10.1186/s12944-026-02927-0 Source material

Publications

1 publication citing this product

  1. Liujie Zheng, .et al. , The FASEB Journal, 2026, 40(4): e71580 PMID: 41677398

Added to your cart

View Cart Checkout
Loading...